Crystalline forms of 'r-(r,r)-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin

本发明描述了用X-射线粉末衍射、固态NMR和/或拉曼光谱表征的称为晶形V、晶形VI、晶形VII、晶形VIII、晶形IX、晶形X、晶形XI、晶形XII、晶形XIII、晶形XIV、晶形XV、晶形XVI、晶形XVII、晶形XVIII及晶形XIX的[R-(R*、R*)]-2-(4-氟苯基)-β，δ-二羟基-5-(1-甲基乙基)-3-苯基-4-[(苯基氨基)羰基]-1H-吡咯-1-庚酸半钙盐阿托伐他汀的新颖晶形，以及描述了它们的制备方法和它们的药物组合物，这些新颖晶形用作治疗血脂过多症、血胆固醇过多症、骨质疏松症及阿耳茨海默病的药剂。 Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-², ”;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt atorvastatin designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.